Endonovo Therapeutics, Inc. (ENDV): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

Not updated since 2022-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2015-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest Free Cash Flow is for the year ended 2019-12-31, while the company's latest annual report covers the year ended 2022-12-31. Its later filings do not report Capital Expenditures, which Free Cash Flow is computed from, under the concepts TickerFacts maps.